PCOS & Infertility, CLR 131 in pediatric cancers and CRISPR-edited immune cells
AUGUST 25, 2021

Prevention and Management of PCOS Related Infertility – A Q&A Session

with  Dr. Ilana Ressler
Sep 1, 2021, 4 PM EST

Polycystic ovary syndrome (PCOS) is a chronic disorder affecting 1 in 10 women of reproductive age. It is the primary cause of reduced frequency of ovulation and anovulation at the reproductive age and is commonly associated with infertility. The prevalence of infertility in women with PCOS varies between 70 and 80%. Can early PCOS diagnosis prevent related infertility? How can the wait period before family building be reduced? What are the treatment options for women dealing with PCOS related infertility? We are talking to board certified reproductive endocrinologist Dr. Ilana Ressler of RMACT, who will help answer these and other related questions from the PCOS community. Dr Ressler will help us learn all about the prevention, diagnosis, treatment and management of infertility occurring as a result of PCOS that went undiagnosed or was diagnosed late. 


Dr. Ilana Ressler 
Lisa Rosenthal
Tatiana Alafouzo
Dr. Ami Patel
Shweta Mishra 
July 12, 2021, 1:00 pm EST
Many pediatric cancers have very poor overall survival rates once they relapse or if they do not respond to initial standard treatments. Radiotherapy plays an important role in the treatment of these cancers. However, if the cancer has metastasized to many sites, external beam radiotherapy becomes impracticable and too harmful to healthy body tissues. CLR 131 by Cellectar Biosciences, is a radio iodinated therapeutic that selectively delivers radiation to malignant tumor cells, thus minimizing radiation exposure to normal tissues. It consists of a cancer-targeted small-molecule compound radiolabeled with isotope iodine-131. CLR 131 has demonstrated tumor selective uptake and therapeutic efficacy in various pediatric cancers. We talked to Dr. Mario Otto, University of Wisconsin School of Medicine and Public Health and Dr. Daniel Morgenstern, SickKids about use of CLR 131 in pediatric cancers, status on the clinical trials and scope of targeted radiotherapeutics in pediatric cancers.

Dr. Mario Otto
Dr. Daniel Morgenstern
Jeremy Pivor
Mark Unger
Shweta Mishra
Jun 29, 2021, 10:00 am EST
The Nobel prize winning CRISPR-Cas9 genome editing system is being explored for its potential use in cancer research and treatment. By deleting, inactivating, or otherwise modifying specific genes in cultured cells or in animal models, researchers have been able to study the role of these genes in cancer development and progression, providing insight into how to prevent or treat certain cancers. The research team at University of Pennsylvania have been using CRISPR editing to improve the effectiveness of gene therapies for cancer. The latest preliminary data from their study show that removing genes known to stifle T cell activation on CAR T cells enhanced the engineered T cells’s ability to eliminate blood cancers. CureTalks panel talks to Dr. Edward A. Stadtmauer from University of Pennsylvania about CRISPR-Cas9 gene editing system and scope of the tool in cancer treatment and management.

Dr. Edward A. Stadtmauer
Matt Goldman
Jennifer Zarou
Maddie Hunter
Priya Menon
Subscribe to CureTalks YouTube channel here.
Our Picks
TrialX Editor